On 12 May 2026, one of the most significant renamings in modern medical history appeared in The Lancet. Polycystic Ovary Syndrome, or PCOS, is now officially called Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The announcement came at the European Congress of Endocrinology in Prague and was endorsed by 56 major academic, clinical and patient organisations, including the Endocrine Society. It took 14 years and involved more than 22,000 patients, clinicians, researchers and advocates across six continents. And while the shift from one acronym to another might seem small, its implications for how the condition is diagnosed, treated, funded and understood are anything but. Technology, especially the FemTech sector, played a quiet but important role in bringing this about.
PCOS vs PMOS
The name Polycystic Ovary Syndrome was always misleading. The so-called ‘cysts’ it referred to were not abnormal cysts at all, but follicles containing eggs whose development had been halted due to broader hormonal disruption. As Professor Helena Teede, the endocrinologist at Monash University who led the renaming process, explained, the sacs were simply evidence of the condition’s underlying endocrine dysfunction, not its defining feature. This distinction may sound technical, but its consequences were very practical. Patients without visible follicles on ultrasound were often told they could not have PCOS, even when they showed every other sign of the condition. Clinicians focused diagnostic attention on ovarian morphology when the real drivers (insulin resistance androgen excess and disrupted neuroendocrine signalling) were not being properly assessed.
Stigma and Delayed Diagnosis of The Name PCOS
The Lancet paper, authored by Professor Teede and colleagues, describes the old name (PCOS) as ‘inaccurate, implying pathological ovarian cysts and contributing to delayed diagnosis, fragmented care and stigma, while curtailing research and policy framing.’ The average time from first symptoms to confirmed diagnosis remains up to 12 years in some health systems. Insurance coverage and research funding followed the ovarian framing, limiting which conditions and treatment approaches were studied.
Why the New Name ‘PMOS’ Changes Everything
PMOS — Polyendocrine Metabolic Ovarian Syndrome — was chosen carefully, with each word carrying meaning.
Meaning of Polyendocrine (in PMOS)
‘Polyendocrine’ recognises that the condition involves multiple interacting hormonal systems, not a single ovarian issue.
Meaning of Metabolic (in PMOS)
‘M’ stands for ‘Metabolic’, in PMOS and it acknowledges its strong cardiometabolic dimension — the elevated risks of type 2 diabetes, cardiovascular disease and insulin resistance that make this a whole-body condition.
Meaning of Ovarian (in PMOS)
‘Ovarian’, the ‘O’ in PMOS, remains to preserve continuity and reflect the condition’s reproductive aspect.
The Endocrine Society, Verity (PCOS UK), the International Androgen Excess and PCOS Society and more than fifty other organisations endorsed the change.
Understanding How PCOS Was Renamed to PMOS
It didn’t happen over night and it was a 14-year global consensus process. The push for a name change was first raised at a National Institutes of Health meeting in 2012. What followed was one of the most rigorous and inclusive consensus efforts in modern medical naming: three rounds of global surveys in 2017, 2023 and 2025, a modified Delphi methodology, nominal group technique workshops and marketing and communication assessments to test how proposed names would resonate across populations and languages.
The final survey in 2025 reached nearly 15,000 stakeholders. In total, over 22,000 people were consulted throughout the process.
Patient Voices Were Central
What makes the PMOS renaming stand out from many other medical nomenclature changes is how deeply lived experience was built into the process from the start. Rachel Morman, Chair of Verity (PCOS UK), served as an active co-lead on the global process. The principle that patient voices should hold equal weight with clinical and academic ones in deciding how a condition is named was applied in practice, not just stated in theory. That is rare in medical history and it helps explain why the outcome has been so widely accepted.
How FemTech Assisted in PCOS to PMOS Renaming
The PMOS renaming did not happen in isolation from the technological revolution in women’s health. One of the consistent barriers to diagnosing what was called PCOS was the fragmentation of its symptoms, with irregular periods seen by one clinician, acne by another, weight resistance by a third and mood disturbance by a fourth. No single clinician saw the full picture because patients moved through a fragmented system.
FemTech Helped Track PMOS Symptoms
Femtech apps changed that dynamic. Cycle tracking platforms like Clue, Flo and Natural Cycles, with tens of millions of users between them, began generating population-level data on menstrual irregularity, symptom co-occurrence and health-seeking behaviour at a scale that was simply not available to clinical researchers in the pre-smartphone era.
This data helped build a growing evidence base showing that the condition was far more prevalent, more heterogeneous and more metabolically complex than the ovarian-centric model had acknowledged.
AI and Machine Learning Helped Identify Patterns in PMOS Patients
Machine learning models trained on electronic health records repeatedly identified patients with clear PCOS-pattern metabolic and hormonal markers who had never received a diagnosis because they had no ovarian cyst finding on ultrasound. The pattern that AI tools kept surfacing, hormonal disruption without cysts, was precisely the argument for renaming the condition.
How The Digital Age Helped
It is worth noting that the scale of the renaming consultation, 22,000 people across six continents and three rounds of surveys over eight years, would have been practically impossible without modern digital infrastructure. The ability to administer, collect and analyse surveys at that scale, in multiple languages, across all world regions and including both professional and patient populations, is entirely a product of the digital age.
Women’s Health AI Consortium Launched the Same Week
In a development that felt entirely fitting, the same week that the PMOS announcement was made, women’s health leaders announced the launch of the first AI consortium specifically focused on creating standards for safety, bias and transparency in women’s health AI. This consortium, bringing together femtech companies, clinical researchers and patient advocates, is designed to ensure that the AI tools being developed for conditions like PMOS are trained on diverse, representative data and evaluated for fairness across different populations.
What Happens Next?
The renaming of PCOS to PMOs won’t just occur overnight and there is a multi-stage plan to ensure healthcare professionals globally gain relevant education and training on what PMOS stands for and how to diagnose it.
A Three-year Transition Period
PMOS will not replace PCOS overnight. A formal three-year transition period has been established, during which international education and awareness campaigns will be rolled out for health professionals, governments, researchers and the public. The new name will be fully implemented in the International Guideline update in 2028. During this period, PCOS and PMOS will be used in parallel, which will require careful navigation for apps, diagnostic tools and online health platforms that currently use PCOS as a primary search and categorisation term.
Femtech Has a Huge Market Opportunity During This Transition
For the FemTech sector, the renaming creates both a responsibility and an opportunity. Cycle tracking apps, hormone monitoring platforms and AI diagnostic tools that have been built around PCOS-era terminology will need to update their interfaces, search functionality and underlying data models to reflect PMOS. More importantly, the new framing, with its explicit acknowledgement of the metabolic and polyendocrine dimensions of the condition, opens up new directions for product development. PMOS is not just a gynaecological condition. It is a cardiometabolic one, a mental health one and a dermatological one. The femtech companies that build to that complexity, rather than the ovarian-centric model the old name implied, will be the ones that serve the next generation of patients most effectively.
